NAD+ boosters have shown significant results in extending life and healthspan in mice. With the benefits they offer, they can enhance age-related conditions and improve overall health. NMN and NR are highly efficient precursors to NAD+. There is already known and studied NAD precursor on the market available, called NMN, that has shown positive results in treating certain diseases, and effectively increasing the NAD levels. However, scientists aim to develop a new potent formula that will have greater effects in enhancing and raising NAD levels in humans. Therefore, new trials of MIB-626, or a microcrystalline unique polymorph βNMN formulation, have drawn attention for its optimal therapeutic properties in various human diseases including Alzheimer’s, dementia, and other age-related conditions. The preclinical trial supports the potential therapeutic effects of MIB-626.
What is MIB-626?
MIB-626 is the microcrystalline polymorph form of βNMN. It has immunomodulatory and anti-inflammatory properties, as well as it is a stress regulator through numerous pathways. A potent drug that treats Alzheimer’s disease, dementia, and other conditions. Recently, MIB-626 has been very active due to its possible effects.
NAD+ is a molecule that plays a vital role in our body. It is a part of many cellular processes, where it turns nutrients into energy. NAD+ levels decrease as we age, and the body must get it from another source. The best way to replenish NAD+ levels is by NAD+ precursors, including Nicotinamide Riboside (NR) , Nicotinic Acid (NA), Nicotinamide (Nam), Nicotinamide Mononucleotide (NMN), and Tryptophan (Trp). Recently, MIB-626 has become the area of interest because it has been designed to have much greater effects for boosting NAD+ levels, compared to other NAD+ precursors.
MetroBiotech is focusing on developing new and better NAD+ enhancers for treating Alzheimer’s disease. Alzheimer’s disease is a chronic progressive degenerative disease of the brain and most often occurs after the age of 65. Early detection and treatment of Alzheimer’s disease slows its progression and improves the quality of life. By advanced and promising research on new drug discovery, Alzheimer’s can be prevented, treat and cure.
David Sinclar, a professor from Harvard, and MetroBiotech are currently focusing on the new development drug, called MIB-626. MIB-626 is the unique crystalline form of NMN that has anti-inflammatory and immunomodulatory properties. This new and potential NAD booster has completed phase one human clinical trials and currently is in phase two clinical trials. David Sinclar with his colleagues has worked on this drug for years now, testing it in elderly people. The final results from these studies showed positive feedback.
If you want to know more about MIB-626 specifications, such as packaging, purity, shipment, feel free to contact us.
MIB-626 clinical trial
In one double-blind study, 32 obese 55-80 years adults were treated with 1000-mg MIB-626. They were given the current dosage once a day, twice a day, and a placebo for 14 days. In this trial NAD, NMN, and NAD metabolome were measured. The results show well MIB-626 tolerance with no side effects. On the 14th day, the blood NNM concentration in the group that was treated with MIB-626 was higher than placebo. In other words, the NAD and NAD metabolome levels were significantly higher and dose-dependent while treated with MIB-626. Given 1000mg MIB-626 once daily or twice daily was considered a safe dosage. The age, sex, or body mass index do not affect any changes in the results.
Figure 1. Pencina K., Lavu S., Dos S. M., Memish B. Y., Cheng M., Livingston D., Bhasin S. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-aged and Older Adults. J Gerontol A BiolSci Med Sci . 2022 Feb 19;glac049. https://pubmed.ncbi.nlm.nih.gov/35182418/
Another interesting finding is the phase 2a clinical trial of MIB-626 for treating Friedreich’s Ataxia (FA) in adults. This trial focuses on the safety and tolerability of short-term treatment. Ten participants are involved in the study, where several parameters are measured before and after the treatment with MIB-626. In this trial, two 500 mg tablets were given by mouth daily. There is only one group in this trial, without a control group. The whole study will last for 12 days. Several parameters will be measured, including safety (through vital signs, and other laboratory assessments), the level of NAD in skeletal muscles (through oxidative phosphorylation in mitochondria), grip strength, and NAD+ levels in the blood. The investigation is ongoing.
Will MIB-626 dominate the NMN market?
What we know from these studies is that there is a dose-dependent increase in the elevation of NAD when you take MIB-626. According to recent findings, 250mg, 500mg, and 750mg doses of MIB-626 weren’t enough in achieving the desired results, i.e. to raise the NAD levels. While on the other hand, the minimally affected threshold for increasing NAD levels was 1000mg. Because MIB-626 is a new potential drug, additional clinical trials are needed. There are ongoing phase 2 trials at leading hospitals. However, it is FDA-approved.
Is MIB-626 the same as NMN?
We are not sure yet, because parameters such as energy, endurance, etc. are still not tested, so we don’t know what the results will be. Maybe there are some unique effects that we don’t know of yet. It may be different from NMN because MetroBiotech aims to develop a far more potent and efficient NAD booster than other boosters available on the market.
When will MIB-626 be available to buy on the market?
Because the drug undergoes phase two clinical trials, it is believed to be available to buy on the market in 3 years from now.
Where to buy MIB-626 powder?
MetroBiotech is a drug development company, producing highly effective NAD+ boosters in the world. With extensive clinical experience in metabolic pathways, drug development, manufacturing, molecular biology, isotopic labeling, and nucleoside chemistry, has established the best way to increase NAD+ to preserve health and normal metabolism.